Alvotech ehf, of Reykjavik, Iceland and Cipla Gulf FZ LLC, a wholly-owned subsidiary of Mumbai-based Cipla Ltd., said they have entered into an exclusive partnership for the commercialization of AVT-02, a MAb biosimilar to Humira (adalimumab, Abbvie Inc.), in select emerging markets.

Verastem Oncology Inc., of Boston, said it entered an exclusive licensing deal with Paris-based Sanofi SA to develop and commercialize Copiktra (duvelisib), an oral PI3K-delta/gamma inhibitor, for all oncology indications in Russia and CIS, Turkey, the Middle East and Africa. 

Exopharm Ltd., of Melbourne, Australia, said it finalized an AU$4.44 million (US$3.03 million) share placement to new institutional and sophisticated investors. 

Curza Global LLC, of Salt Lake City, received a $5.25 million investment from Novo Holdings Repair Impact Fund to support the advancement of its CZ-02 program that targets multidrug-resistant gram-negative infections.

Alkermes plc, of Dublin, reported second-quarter revenues of $279.9 million compared to $304.6 million for the same period in 2018.

In what it called one of the largest pharmaceutical settlements on behalf of end payers in an antitrust case in the last decade, law firm Hausfeld reported this week that it reached a $55 million settlement with Celgene Corp. in a long-running class action, In re Thalomid and Revlimid Antitrust Litigation.